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The COVID-19 pandemic has generated a lot of demand for responses to 
prevention, treatment, how to control, how to predict evolutions, among others. 
This thesis aims to answer the question about what affects mortality. Thus, 
through the use of Analytics, 26 different variables were studied for 37 duly 
selected countries. The results showed that the country's economic structure has 
no impact on mortality, while vaccination policy for BCG, changes in mobility 
within the country, such as “stay at home”, and the prevalence of diabetes have 
an impact on mortality. 


































A pandemia COVID-19 tem gerado muita procura por respostas para 
prevenção, tratamento, como controlar, como prever evoluções, entre outras. 
Esta tese pretende responder à pergunta sobre o que afeta a mortalidade. Assim, 
através do uso do Analytics foram estudadas 26 diferentes variáveis para 37 
países devidamente selecionados. Os resultados permitiram concluir que a 
estrutura económica do país não tem impacto na mortalidade, enquanto que a 
política de vacinação para a BCG, as alterações da mobilidade dentro do país, tais 
como o “stay at home”, e a prevalência de diabetes têm impacto para a 
mortalidade. 
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Nowadays, the COVID-19 pandemic is strongly present worldwide, and has 
been affecting the way of living, economies, and most important, is being the 
cause of a lot of deaths. There is, on a global scale, a huge concern for seeking 
solutions to this pandemic, including trying to find a vaccine, sometimes trying 
or find the best medication, and also trying to explain how the pandemic evolves, 
among others. 
In this thesis, we seek, through an application of analytics, to explain how 
mortality varies between countries. Thus, we take not only the daily data 
regarding updates of COVID-19 but also seek to introduce variables that 
effectively differentiate the country, both in terms of demographics, economic 
structure, time of response to the pandemic, among others, in order to 
understand which characteristics or even decisions directly affect mortality in 
countries. 
Thus, this thesis is divided into three fundamental parts. In the first part we 
try to define business analytics (BA) and its main tools, then we talk about BA 
applications in healthcare so far. Also, in the first part, we started to focus more 
on the theme of this thesis, an application of business analytics to explain 
mortality by COVID-19, and so we begin to briefly describe the pandemic and 
then present in what ways analytics is being used in this context. Finally, we 
present some studies conducted up to the moment where some seek to predict 
the evolution of the pandemic curve and others seek to find the reasons for the 
differences between results for different countries. 
Then, in section 4, we put forth the method used to estimate the model, how 
the variables to be studied were collected, the choice of the countries studied that 
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were in total 37, the optimization process of the model and finally, the process of 
selecting variables to be included in the model. 
Finally, we present the results of the estimated model, with deaths from 
COVID-19 as a dependent variable. After explaining the results of this model, 
two other models are estimated to see if it is possible to go further to explain 
differences between countries on severity of the disease. The results of these two 
























2. Literature Review 
2.1 Business Analytics 
According to Davenport et al. (2007), Business Analytics (BA) is the use of 
data, statistical analysis, quantitative methods and mathematical or computer-
based models to help managers gain improved insight about their operations so 
they can make better decisions. 
Later, Delen and Demirkan (2013)defined Analytics as a facilitator to draw 
business objectives through the report of data, the analysis of trends and the 
creation of predictive models to better understand future problems and 
opportunities and optimizing processes to increase organizational performance. 
Beyond this definition they were able to notice the rapid evolution of Business 
Analytics and pointed the utility of the data to the decision makers as the main 
reason. With the use of business analytics, it was possible to provide the 
information the decision makers needed and with the guarantee of quality Delen 
and Demirkan (2013). 
Davenport and Patil (2012) went even further declaring data scientist as the 
sexiest job of the 21𝑠𝑡 century.  
In 2014, data were deemed the new oil (Acito and Khatri 2014), by recognizing 
the importance of leveraging value from them, which should require an 
alignment between strategy and desirable business performance with analytic 
tasks and capabilities. 
Finally, Griffin and Wright (2015) pointed business analytics as the influencer 
of almost every aspect of major companies’ decisions, strategies and forecasting.  
 
Business Analytics is a recent trend but has been growing over the last years. 
In 2011, on a survey performed by IBM Tech Trends Report of over 4000 
information technology professionals from 93 countries and 25 industries, 
4 
 
business analytics was identified as one of the four major technology trends in 
the 2010s. 
Still in 2011, on another survey, performed by Bloomberg Businessweek,  
97% of companies with revenues above $100 million were found to use business 
analytics. 
This rapid evolution and growth of business analytic led Hal Varian, Chief 
Economist at Google comment the following: “So what's getting ubiquitous and 
cheap? Data. And what is complementary to data? Analysis. So, my 
recommendation is to take lots of courses about how to manipulate and analyze 
data: databases, machine learning, econometrics, statistics, visualization, and so 
on.” 
On 2014, a search on google scholar suggested 19400 articles published on 
business analytics since 2012, which is about one article per hour over two years. 
(Acito and Khatri 2014). Doing the research nowadays (April, 2020) we can see 
that there are a total of 736000 articles published in the field of business analytics 
where 34800 were posted since 2019. 
 
So, it is clear that Business Analytics is getting increasingly useful and used on 
these days, but how does it work? 
Having the big data extracted from both internal and external data sources, it 
is possible for managers to utilize data analytics techniques in order to answer 
questions like, what has happened, what will happen and what are the optimized 
solutions. These questions are usually grouped into three dimensions of business 
analytics, descriptive analytics, predictive analytics and prescriptive analytics 







Descriptive analytics is the most used approach to business analytics and it 
usually uses descriptive statistics, dashboards and other types of visualizations 
(Dilla, Janvrin, and Raschke 2010). 
The main output of a descriptive  analysis is to identify business opportunities 
and problems (Delen and Demirkan 2013) and also to find an answer for what 
happened/is happening (Souza 2014) by analyzing the data collected. 
2.1.2Predictive Analytics 
This analytics approach is the next step after the knowledge provided by 
descriptive analytics. 
Predictive analytics is used to answer the question of what will be happening 
and why it will be happening (Souza 2014) using data and mathematical 
techniques, data mining and statistical timeseries forecasting to project the future 
(Delen and Demirkan 2013). 
Predictive models calculate probability of future events using historical data 
collected over  time Appelbaum et al. (2017). 
 
2.1.3 Prescriptive Analytics 
Prescriptive analytics is about making decisions based on both descriptive and 
predictive models and mathematical optimization models (Souza, 2014). 
The main output of this analysis is a course of action given a specific situation 
or an amount of information that is provided to a decision maker (Delen and 
Demirkan 2013). 
Despite the techniques and tools for predictive and prescriptive analytics may 
seem similar ,“The main difference between prescriptive and predictive analytics 
is not one of required data types, but one of orientation – that is, is this an 




The three dimensions of Business Analytics can be summarized as follows: 
 







Question What happened in the 
past? / What is 
happening now? 
What will happen in 
the future? Why it will 
happen in the future? 
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2.2. Business Analytics in Healthcare  
Nowadays we can easily collect and analyze data, and the role of Business 
Analytics in Healthcare should be to transform that data in order to improve 
healthcare delivery. There are many sectors that benefit from the use of analytics, 
but healthcare is probably one of the sectors where analytics can have a bigger 
impact. The analytics in healthcare is of utmost importance given the existence 
of large amounts of data. 
Ward, Marsolo, and Froehle (2014), mentioned seven different platforms for 
data generation in the healthcare context: 
Table 2- Example of data sources within a healthcare delivery system (Ward, Marsolo, and Froehle 2014) 
Data source Data Generated 
EHRs (electronic health 
record) 











Range from images (e.g., magnetic resonance imaging) to numbers 
(e.g., vital signs) to text report (result interpretation). May or may not 
be interfaced with EHRs. 
Insurance 
claims/billing 
Information on what was done to the patient during a visit, the cost 
of those services and the expected payment. The level of service is 
often determined from data in EHRs. 
Pharmacy Information on the fulfillment of medication orders. Not typically 
part of EHRs. 
Human resources and 
supply chain 
Lists of employees and their roles in the institution and the location 
and utilization of medical supplies. Not typically interfaced with 
EHRs. 
Real- time locating 
systems 








Meanwhile, on a systematic review regarding big data analytics and 
healthcare, and after selecting 58 articles out of 12390, Mehta and Pandit (2018) 
pointed to the following data sources. 
Table 3- Sources of Healthcare  (Mehta and Pandit 2018) 
Data Sourced Data Generated 
EMRs Detailed patient-related information (physician prescriptions, 
medications, medical history) 
Diagnostic Diagnostic Results (imaging results, laboratory reports) 
Biomarkers Molecular data (genomic, proteomic, transcriptomic, 
metabolomic) 
Ancillary Administrative data (admission, discharge, transfer) & financial 
data (claims) 




Prescription reimbursement data (drugs, dose, duration) 
Clinical Trails Design parameters (compound, size, end points) 
Social Media Community discussions 
Wearable & 
Sensors 
Wellness & lifestyle data (smartphones, fitness monitors)  
 
Having the data sources set, Mehta and Pandit (2018) and Ward, Marsolo, and 
Froehle (2014)  found the same applications for business. 
Ward et al. (2014) distinguish the different uses that Analytics have on the field 
of Healthcare, which we highlight below: 
 
• Dashboards and control charts 
• Genetics 
• Cost of treatment and guiding investments 
• Chronic disease databases 
• Disaster planning 
• Patient flow 
• RFID (Radio-Frequency identification) 
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Charts allow the visualization of data in real-time which helps on making 
decisions faster. Charts are a widget type on a dashboard that display trends 
and metrics in live data. 
In the case of Healthcare, control charts and dashboards are used to monitor 
outcomes so the Hospital can have information on patient waiting times, rooms 
utilization, operational metrics, etc. 
Figure 1-Open Saint Martins Clinical Performance Dashboard in 2016 from: 
https://www.datapine.com/dashboard-examples-and-templates/healthcare 
 
In Figure 1 it is possible to see a Dashboard from Saint Martins Clinic the KPI’s 
of the organization are shown. Another type of dashboard could have been 
Patient Satisfaction Dashboard, which allows the managers of the Hospital to 
know how their service is being evaluated by the patients in what aspects they 
should improve. 
 
According to Ward, Marsolo, and Froehle (2014) integrating genetic data into 
healthcare practices provides a lot of interesting possibilities for the field of 
analytics, like testing on risk factors for certain genetic conditions. 
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Furthermore, by using patient’s genomic information it is possible to build 
individualized strategies for each patient since big data, trough the examination 
of large data sets uncovers unknow correlations, hidden patterns which make it 
possible to get some other insights (He, Ge, and He 2017). 
 
Analytics can be used in healthcare in a more managerial way, in order to 
compare the costs and effectiveness of medical devices, treatments, 
interventions, etc. One example is that an hospital can choose to stop utilizing 
some replacement hips by comparing its cost and performance and exclude the 
ones that cost more and provide less outcomes for patients (Ward, Marsolo, and 
Froehle 2014) 
 
The use of analytics in chronic diseases consists in having a large database that 
allow the creation of tools and processes to better support and supervise the 
patient along its chronic disease.  This support and supervision is done by using 
the data to improve the quality of information during the patient encounter, 
develop personalized software applications, estimate comparative treatment 
effects of biologic agents and to develop governance and data-sharing processes 
(Ward, Marsolo, and Froehle 2014) 
 
Another example where analytics can play an important role is in situations of 
disaster which can occur in different forms like hurricanes, terrorist attacks, 
airplane crashes, infectious diseases and so on. Given the current situation, the 
spread of COVID-19 worldwide, an infectious disease that cause respiratory 
failure, the use of ventilator to assist with breathing until a patient recover can be 
really required and vital.  
 In these cases, having a real-time data on the availability of ventilators and 
other equipment and resources within a location can result in a more efficient 
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way to organize resources and so resulting on improved outcomes and the 
avoidance of deleterious outcomes in consequence of delayed treatments (Ward, 
Marsolo, and Froehle 2014) which can save lives. 
 
For decades, the management of resources in healthcare facilities has been 
affected by the lack of knowledge of the managers on the resources needed and 
staff. (Ward, Marsolo, and Froehle 2014)  
The improvement of patient flow, the reduction of waiting and the potential 
improvement of patient outcomes have been becoming a reality with the use of 
analytical tools like closed-form mathematical modelling and empirical and 
statistical analyses (Froehle and Magazine 2013). Another application of analytics 
is the use of predictive analytics to forecast and plan for excessive patient waiting 
in emergency departments, in order to build and observation unit for patients 
requiring abbreviated admissions (Hoot et al. 2008). 
 
Beyond asset management, Radio Frequency Identification (RFIC) is being 
integrated into healthcare in order to provide real-time identification and 
tracking of patients and staff.  
Applying this real-time tracking to analytics, it can be used for example to 
evaluate potential retained surgical equipment (Rogers, Jones, and Oleynikov 
2007) and for patients with chronic diseases like diabetes and hypertension that 
can be monitored for achieving specific numeric targets in their blood sugar and 
blood pressure (Moore 2009). 
In these devices, the main issues are the accuracy of data and privacy issues 





3. COVID-19 Case  
Coronavirus Disease 2019 (COVID-19) recognized in December 2019, is 
the latest threat to global health and it seems to be caused by a novel coronavirus 
that is structurally related to the virus that causes severe acute respiratory 
syndrome (Fauci, Lane, and Redfield 2020). 
There are strike similarities between COVID-19 and others infectious 
respiratory diseases like SARS (severe acute respiratory syndrome) but its 
differences determined whether to use the same measures used for SARS or not. 
COVID-19 has a bigger infectious period, transmissibility, clinical severity and 
extent of community spread (Wilder-Smith, Chiew, and Lee 2020) 
The novelty of the epidemic situation that the world is living is demanding a 
response from health services and institutions (to treat patients and to study and 
research vaccines and treatments), but also from other researchers outside the 
health system. In particular, data scientists have been very active during this 
period, because the enormous amount of data that has been generated needs to 
be analyzed, displayed and treated to inform the governments, managers, 
healthcare decision makers and the population. In the next sections we will 
outline the main analytic tools that have been provided in the various areas of 












3.1The use of analytics in COVID-19 
 
The World Health Organization (WHO) provides daily situation reports since 
21 January 2020. In all reports the first page highlights the most important topics 
and provides a global situation in numbers for the world and for regions like the 
total number of cases confirmed per region, total number of deaths confirmed 
per region, new cases in last 24 hours confirmed per region and new cases in last 
24 hours of deaths per region. It also shows a map where it is possible to note the 
most affected areas in the last seven days. 




Figure 2 - WHO daily report 
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On the following pages, the report has a table with Countries, territories or 
areas with reported laboratory-confirmed COVID-19 cases and deaths for 12 
April 2020. The table provides  for all countries, territories and areas affected with 
COVID-19 information regarding total cases confirmed including both domestic 
and repatriated cases, total confirmed new cases, total deaths, total new deaths, 
transmission classification which can be no cases, sporadic cases, clusters of cases or 
community transmission and days since last reported case. 
Figure 3 shows part of a table included on the 12 April 2020 situation report of 
WHO. 
 








And finally, WHO provides a Graph that shows the epidemic curve of 
confirmed COVID-19, by date of report an WHO region through, in this case, 12 
April 2020 as in Figure 4. 
 
 
Figure 4-Epidemic curve of confirmed COVID-19 by date 
 
Dashboards have been very utilized to show the data from coronavirus 
worldwide. They are simple to read and have all the information gathered with 
a dynamic form of analysis and interaction. 
Figure 5 shows another dashboard, created by the Johns Hopkins University, of 
the worldwide situation of COVID-13 on April 30.  




In this dashboard it is possible to find information on total confirmed cases 
worldwide, total confirmed cases in every country, total deaths and recovered 
worldwide, total deaths and recovered by country, total testes result in US and 
hospitalization by states in US. 
In the map in red we can see the most affected areas, and below the map we can 
choose different tabs that give us information of Cumulative confirmed cases, 
active cases, incidence rate, case-fatality ratio, testing rate and hospitalization 
rate,  where all these are for each country except the last two, testing and 
hospitalizations which are only for the US. 
Dashboards have been widely used in COVID-19 and not only global dashboards 
are available but also country specific ones. For example, in Portugal, COTEC 
provides 4 different kinds of dashboards. 
The first one is figure 6, where COTEC presents the evolution in time, since 
March 15, of deaths, recoveries, active cases and growth of COVID-19 cases 
nationally. 
 




Furthermore, in the header they provided the real time data of total suspects, 
total confirmed, new cases, growth of cases of COVID-19, hospitalizations, 
hospitalizations in ICU, total deaths, lethality and total recoveries.  
By clicking in any of the days on the below graph, the header changes for the 
data of that specific day. 
 
The second one, in figure 7, provides the evolution of all the data in the header 
with six different graphs representing the evolution over time of:  
(1) Confirmed cases and new cases; 
(2) Suspected cases, confirmed cases and the ratio between both confirmed 
cases and suspected cases; 
(3) Recoveries and in recover; 
(4) Hospitalizations and the ratio of hospitalizations by confirmed cases; 
(5) Deaths and lethality; 
(6) Hospitalizations, hospitalizations in ICU and the ratio between both. 
 





Beyond the COVID-19 global state and temporal analysis in Portugal presented 
above, in the third dashboard COTEC provides age and gender analysis. 
 
Figure 8- Age and gender analysis 
In this dashboard it is possible to find confirmed cases, deaths and lethality 
per age group, the percentage of symptoms felt, the confirmed cases per date and 
age group and finally the percentage of symptoms per date. 
 
Finally, in the last dashboard COTEC shows the geographic distribution of 
cases in Portugal.  
Figure 9- Geographic analysis 
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In this dashboard we can find the number of cases per city, a Portugal map 
with graduation colours showing the most affected areas (in dark orange and 
red), and lastly the confirmed cases and deaths per region. 
 
3.2 Previous studies on the explanation of differences between countries 
As this thesis will be an application of Analytics tools to explain differences 
observed between countries on their mortality and severity cases, in this point 
we review evidence from previous studies, to better conduct the thesis. 
The previous studies are grouped according to two different criteria: 
Studies that use econometric methods and prediction algorithms to predict the 
evolution of curves. 
Studies that explain the constraints and differences between results for 
different countries. 
 
3.2.1 Applying econometric method and prediction algorithms to predict the 
evolution of curves. 
Shojaee et al. (2020) predict the mortality due to COVID-19 for the next month 
for Italy, Iran and South Korea using their current situation. 
The method that the authors use is a simple linear regression model to predict 
the slope of the regression lines in the upcoming days. 
Their analysis was performed from March 15 to April 15 using Rami Krispin 
dataset where they arranged results for the upcoming 10, 20 and 30 days 
regarding the current scenario in each country. 
Given the situation it is possible to compare the predicted scenarios with the 
real ones by using the information provided by WHO and their situation reports 
that are daily published. To do the comparison, for 10 day it was used the 
situation report of 25 March of WHO, for 20 days it was used the situation report 
of 4 April and for 30 days it was used the situation report of 15 April. 
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Table 4 and 5 illustrate the results of Shojaee et al. (2020) and the situation 
report of WHO for both confirmed cases and death cases. 
Table 4- Comparison of total cases between the prediction of Shojaee et al. (2020) and the situation report of WHO 


















Italy 61725(357) 69176 114803(865) 119827 183979(1580) 162488 
South Korea 11419(98) 9137 14807(221) 10156 18327(379) 10591 
Iran 28788(303) 24811 48226(823) 53183 72251(1605) 74877 
 
Table 5- Comparison of total deaths between the prediction of Shojaee, Pourhoseingholi et al. (2020) and the 
situation report of WHO 


















Italy 4840(99) 6820 9249(240) 14681 18395(437) 21069 
South Korea 130(13) 126 199(29) 177 283(51) 225 
Iran 2215(91) 1934 4562(255) 3294 7770(502) 4683 
It is possible to see that using their model, the confirmed cases in South Korea 
were overestimate for all phases. Despite that, for death cases the prediction was 
very closed to the reality. 
  The opposite happened for Italy were they underestimate with huge 
differences both new and death cases for almost every phases, just 
overestimating the number of cases, again for huge difference, on the third phase, 
the 30 days prediction. 
For Iran they overestimated death cases in all phases and in the first phase of 
new cases, and then they underestimate the results for both second and third 
phases of new cases. These predictions were somehow a little disparate from the 
reality which shows the difficulty of predicting the situation of a pandemic.  
 
On the contrary, Luo (2020), since April 18, has been predicting the end of 
COVID-19 for several countries updating predictions daily, with the latest data. 
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Having in mind that the spread of coronavirus is dependent on several factors, 
like government measures, individuals’ behaviors and even natural limitations 
of the virus, Luo (2020) decided to adapt his prediction regarding daily changes 
and new data worldwide. 
For predicting the situation, Luo (2020) used SIR (susceptible-infected-
recovered) model which incorporates two different parameters which are the 
responsible for the shape of a specific life cycle curve. The parameters can be 
regressed based on the available and actual data of a country, where, in this case, 
the author only reported regressions with satisfactory goodness-of-fit and with 
statistical significance. The result is the determination of a full pandemic life cycle 
where the initial side of the curve is the data collected up to the moment, and the 
rest of the curve is the predicted data.  
By analyzing the curve, it is possible to get information on the date to reach 
the last case, the date to reach 97% of the total expected cases and the date to 
reach 99% of the total expected cases. In Figure 10 it is shown the result of the 
















Figure 10- Lou's prediction for Italy on April 30 
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3.2.2 Explaining the constraints and differences between results for different countries. 
When comparing SARS with the situation of COVID19 in China, based on 
observation of the confirmed cases and deaths, by January 30, 2020 the case 
numbers of COVID-19 had already surpassed those of SARS and according to 
Wilder-Smith, Chiew, and Lee (2020) it could be explained for several reasons: 
• The epicenter of COVID-19 was in Wuhan, the largest city in central China 
with more than 11 million people. This city is a center for industry and 
commerce and has the largest train station, biggest airport and largest 
deep-water port in central China having triplicated its urban population 
in the past decade. 
• As hospital were overwhelmed, and as a result of lack of beds, many 
patients weren’t hospitalized and contributed to seeding in community. 
• Another reason is the infectious period. While in SARS, despite there were 
asymptomatic patients, the transmission occurred from symptomatic ones 
who could easily be identified, in the case of COVID-19 the situation is 
quite different, where transmission during the early phase of illness also 
contributes to the overall transmission which means that isolation of 
symptomatic patients might be too late.  
• Also, the transmissibility might be higher for COVID-19 than for SARS, 
where 𝑅0, which is a central concept in infectious disease epidemiology 
and indicates the risk of an infectious agent with respect to its epidemical 
potential was found to be 3,28 for COVID-19 while it was 3 for SARS. 
• Finally, SARS was mainly an outbreak propagated within hospitals while 
COVID-19 is already spread in community. 
 
Wilder-Smith, Chiew, and Lee (2020) conclude that the lockdown in China was 
resulting in a daily decline of new cases since mid-February showing that China 
was on the right path and that the other countries should be aware and reduce 
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the spread of COVID-19 by implementing early case detection, prompt isolation 
of ill people, comprehensive contact tracing and immediate quarantine of all 
contacts.   
So, the focus for countries should be the containment of COVID-19 since the 
short-term costs of containment will be far lower than long-costs of non-
containment. This means the closure of public places, institutions and restrictions 
in travel and trade, but governments should be aware that these measures can’t 
last too much. So, in an initial phase it is important to contain as much as possible 
the outbreak of COVID-19  which will give time to health systems to scale up and 
be more prepared to respond to every needs, and will minimize the size of 
outbreak reducing the peak incidence which can reduce  global deaths (Wilder-
Smith, Chiew, and Lee 2020). 
 
 Majumder et al. (2015), on a sample of 159 patients with MERS in South 
Korea conclude that towards the middle east respiratory syndrome (MERS) 
outbreak in South Korea in 2015, infected people with pre-existing concurrent 
health conditions and with older age were risk factors for death. 
 Mizumoto et al. (2015), when comprising the outcomes of 185 patients 
with MERS in South Korea conclude that senior persons aged 60 or over were 
9,3-fold more likely to die compared to younger cases and people under 
treatment were 7,8-fold more likely to die than others. 
Fang, Karakiulakis, and Roth (2020) by analysing the results of three studies for 
patients in Wuhan, noted that diabetes was the most common comorbidity 
associated with patients in intensive care due to COVID-19. In the first study, 
Yang, Yu, et al. (2020), observed that in a group of 52 intensive care unit patients 
with COVID-19,  where 32 patients didn’t survived, 22% of those  had diabetes 
and another 22% of those  had cerebrovascular diseases. In the second study, 
Guan et al. (2020), observed that in a group of 1099 patients with COVID-19, 
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where 173 of them had severe disease, 23,7% of those had hypertension, 16,2% 
had diabetes and 5,8% had coronary heart diseases. Finally, in the third study, 
Zhang et al. (2020) observed that 30% of 140 patients admitted to hospital with 
COVID-19 had hypertension and 12% of those patients had diabetes. 
 
Shet et al. (2020), based on evidence that Bacille Calmette Guérin (BCG) vaccine 
has had some sort of protective effects against infections in the past, as well as 
against tuberculosis, the authors built a simple log-linear regression model to 
understand the association of BCG use and the mortality of COVID-19 for 
different countries’ economic status (GDP per capita), different countries’ 
proportion of elderly among the population and different status of 
epidemiological timeline. 
 




In the case of GDP per capita , Shet et al. (2020), had counterintuitive results 
in the analysis of the association between mortality and country economic status 
– “Association between COVID-19-attributable mortality and BCG use in national 
immunization schedules, propotion of population aged ≥65years, time trajectory on the 
epidemiological curve and country-specific GDP per capita. Each dot is representative of a 
country. Red dots=BCG-using countries; Blue dots=Non BCG-using countries.”(Shet, Ray et al. 2020) 
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since higher mortality rates happened in countries with higher GDP (see Figure 
11 - right side).   
The opposite happened for Sonego et al. (2015) that have found evidence that  
the risk of death from acute respiratory illness in children in low-and middle-
income countries is higher and for Khaltaev and Axelrod (2019) whose found that 
low-and middle-income countries have a higher risk of mortality of chronic 
respiratory diseases due to life style, socio-demographic and economic risk 
factors. 
However, on the left side of Figure 10, regarding age, the authors find age over 
65 years to be an important factor. And finally, after all the adjustments the 
authors conclude that it could be found a significant association between 
countries using BCG and lower COVID-19 mortality. 
 
 
When studying the drivers of COVID-19 progression, to a sample of 93 
patients in Wuhan, Yang, Liu, et al. (2020) concluded that NLR (Neutrophil-
lymphocyte ratio) and age were good predictors to prognosis and evaluate the 
severity of clinical symptoms in COVID-19 patients, concluding that these factors 
may be related to the severity of the infection and the outcome of the condition. 
Logistic regression was applied in this study. 
In addition, Al-Najjar and Al-Rousan (2020), collected data between February 
20 and March 9, in order to get into a classifier prediction model to predict the 
status of   COVID-19 patients in South Korea. 
They used different independent variables such as country, infection reason 
(transmission way), sex, group, confirmation date, birth year and region, and, the 
dependent variable was one of the following, death or recovered. 
The authors split the data into a training and a test data sets, and then used 
the training set to build one hidden layer neural network classifier for predicting 
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death and recovered cases. The great accuracy of both training and testing data 
showed that the proposed models for both death and recovered cases had the   
ability to classify the death and recovered cases based on the variables selected.  
By analyzing the results it was found that the main variables for death cases 
were infection reason, confirmation date and region while for recovered cases the 
main effective variables were region, birth year and confirmation date (Al-Najjar 
and Al-Rousan 2020).The authors conclude that by choosing the most effective 
categorical variables and numerical variables could enhance the prediction 
model but if they had some variables with less importance, they could stabilize 
a neural network predictor and avoid overfitting which would result on an 
improved prediction output. 
 
4 Methodology 
4.1Case study purpose 
The purpose of this thesis is to find evidence to explain mortality by COVID-
19 and the factors that affect it globally. Having the knowledge that each country 
has its specific characteristics, the purpose of this thesis is to answer these 
questions: 
• Does economic structure affect the mortality by COVID-19 of the 
country? 
• Do healthcare resources of each country affect its COVID-19 mortality? 
• Is there any comorbidity associated with mortality by COVID-19? 
• Does government response time affect mortality by COVID-19? 









COV19 mortality rates will be explained by panel data regression models since 
they model information on individual behaviour, both across individuals and 
over time. 
The package used in R to estimate the model was plm, a package that 
automates some of basic data management tasks as lagging, summing and 
others, (Croissant and Millo 2008). 
The model can be described as following: 
(1) 𝑌𝑐,𝑤 =  𝛽0 + ∑ 𝛽𝑗  𝑋𝑗,𝑐,𝑤−𝑙𝑗
𝑝
𝑗=1 + ∑ 𝛽𝑗 𝑍𝑗,𝑐 + 𝑢𝑐,𝑤
𝑞
𝑗=𝑝+1  
(2)     𝑢𝑐,𝑤=µ𝑐 + 𝑣𝑐,𝑤 
Table 6- The one-way error component model adapted from Clower, (2019) 
𝛽0 Parameter which measures an intercept that is constant across all 
coutries and weeks. 
𝛽𝑗 Parameter that measures the impact of the time-varying variable Xj, or 
the time-invariante variable Zj, on Y. It is constant across all countries 
and weeks. 
µ𝑐 Country-specific variation in Y which stays constant across time for 
each country. 
 In the random effects model this follows a random distribution with 
parameters that must be estimated. 
𝑣𝑐,𝑤 Usual stochastic regression disturbance which varies across weeks and 
countries. 
 
Where c is the individual, in this case, the country, w(1,...,T) is the time index, 
in this case, week_1st and 𝑢𝑐,𝑤 is a random disturbance term of mean 0. 
Regarding time index, week_1st , this variable was considered in order to 
estimate the model to be on an equal footing for all countries. Thus, instead of 
the model being estimated with the effective weeks (from 1 to 22 weeks from the 
first case in the world in December 30, 2019, until the end of week 22 in May 31, 
2020), for each country week 0 equals the week in which there was the first death 
by COVID-19 in that country, and the other weeks were counted from then on. 
In addition, since to explain deaths in week 0 we needed to use past data, we 
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considered 6 weeks of data before week 0 for all countries, and as a result our 
data set starts in week -6 for all countries considered. 
To better explain this variable let’s look at the situation of Portugal in table 7: 
Table 7- Variable week_1st for Portugal 
Country week_1st week cases deaths 
Portugal na 0 0 0 
Portugal na 1 0 0 
Portugal na 2 0 0 
Portugal na 3 0 0 
Portugal na 4 0 0 
Portugal na 5 0 0 
Portugal -6 6 0 0 
Portugal -5 7 0 0 
Portugal -4 8 0 0 
Portugal -3 9 0 0 
Portugal -2 10 21 0 
Portugal -1 11 148 0 
Portugal 0 12 1111 12 
Portugal 1 13 3890 88 
Portugal 2 14 5354 166 
Portugal 3 15 5463 204 
Portugal 4 16 3698 217 
Portugal 5 17 3998 216 
Portugal 6 18 1507 120 
Portugal 7 19 2216 103 
Portugal 8 20 1404 77 
Portugal 9 21 1661 99 
Portugal 10 22 1732 94 
 
In Table 7, the week that corresponds to 0 in the variable week_1st corresponds 
to week 12 of COVID-19 worldwide. If we used the variable week for all countries 
and not the variable week_1st we would be comparing countries in completely 
unequal states of disease. 
Panel data models can be estimated using fixed effects or random effects. In 
this case it was used random effects since is the only one which considers the 
effect of constant variables which are many in this study. Furthermore, using 
random effects models the country effect (𝑢𝑐) is modelled by a normal 
distribution where uc,w are not correlated with the explanatory variables, which 
will be verified by the Hausman test. 
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4.2 Collected variables 
Taking into account that in a pandemic situation, especially in the case of 
COVID-19 and its rapid spread, there are many factors that seem to affect the 
country's reaction to the situation and its mortality rate, for the construction of 
the model for the explanation of mortality rates by COVID-19, were collected not 
only the data of COVID-19 tracking like cases, deaths, tests and hospitalizations but 
also data regarding demographic characteristics of the country, health system 
capacity, country structure and other variables mentioned in other studies as 
possible causes of the evolution or mortality rate of COVID-19 in certain 
countries. 
 
Variables were collected according to at least one of the following criteria:  
(1) Data regarding the current situation of COVID-19 ; 
(2) Socio-economic and public structure of the country; 
(3) Demographic characteristics of the country; 
(4) Changes in mobility as a result of isolation caused by COVID-19; 
(5) Variables pointed out in other studies as influencing the country's 
performance against the pandemic, COVID-19. 
So, the variables collected are these indicated in table 8 with their respective 
source. 
Table 8- Variables and their sources 
Variable code Variable description Source 
cases Number of weekly 
COVID-19 cases 
 
European Centre for 
Disease Prevention and 
Control  
deaths Number of weekly 
COVID-19 deaths 
European Centre for 
Disease Prevention and 
Control 








admin Number of patients 
weekly admitted to 
hospital with COVID-19 
diagnosis 
Institute for Health Metrics 
and Evaluation 
bed capacity Number of hospital beds Institute for Health Metrics 
and Evaluation 
uci_capacity Number of UCI beds  Institute for Health Metrics 
and Evaluation 
uci_bed Number of patients 
weekly in intensive care 
units with COVID-19 
Institute for Health Metrics 
and Evaluation 
Days since the first 
case until lockdown 
Number of days that each 
government took to 
decree a national 
lockdown after the first 
case in its country. 
BBC News 
retail Variation in percentage 
of mobility in retail and 
leisure 
Cotec 
grocery Variation in percentage 




parks Variation in percentage 
of mobility in parks 
Cotec 
transit Variation in percentage 
of mobility in public 
transport 
Cotec 
workplace Variation in percentage 
of mobility in workplaces 
Cotec 
residential Variation in percentage 
of mobility in residential 
areas. 
Cotec 
Diabetes_prevalence Percentage of population 
with diabetes. 
Our World in Data 
Percentage older 65 Percentage of population 
aged 65 or over. 
Our World in Data 
Percentage older 70 Percentage of population 
aged 70 or over. 
Our World in Data 
population Population Our World in Data 
population density Population density Our World in Data 
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Percentage RD LRI 
deaths 
Percentage of deaths 
from respiratory diseases 
and low respiratory 
infections 
Our World in Data 
GDP per capita Gross Domestic Product 
per capita 
World Bank Population 
Data 
inv.healthcare in 
percentage of  GDP 
Investment in healthcare 




Investment in healthcare 
per capita 
OECD 
physicians per 1000 
people 
Number of physicians 
per 1000 people. 
Our World in Data 
nurses per 1000 
people 
Number of nurses per 
1000 people. 
Our World in Data 
female smokers Percentage of female 
smokers 
Our World in Data 
male smokers Percentage of male 
smokers. 
Our World in Data 
BCG Number of years each 
country stopped having a 
mandatory national BCG 
vaccination policy for all 
BCG World Atlas 
 
The data was collected for the period ranging from 30 December 2019 until 31 of 
May, 2020. In this period some variables remain constant within country, while 
others change as time passes. In the latter case, the data was aggregated by 
weekly sums. 
Looking at the criteria mentioned above, variables in table 6 can be grouped as: 
(1) Data regarding the current situation of COVID-19 are captured through the 
variables cases, deaths, tests, admin and uci_bed. 
(2) Socio-economic and public structure of the country is shown by the 
variables bed_capacity, uci_capacity, Physicians per 1000 people, Nurses per 
1000 people, GDP, inv healthcare %GDP and inv healthcare per capita. 
Regarding bed_capacity and uci_capacity it is important to note that even 
taking into account that the response of some countries to the pandemic was to 
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increase the available bed capacity in both hospitals and ICUs, the data collected 
for the model are only corresponding to the pre-pandemic period so these 
variations are not accounted for. 
(3) Demographic characteristics of the country can be found in variables 
Percentage older 65, percentage older 70, diabetes_prevalence, percentage of 
RD LRI deaths, female smokers, male smokers, population and population 
density. 
(4) Changes in mobility as a result of isolation caused by COVID-19 are the 
variables retail, grocery, parks, transit, workplace and residential. 
(5) Variables pointed out in other studies as influencing the country's 
performance against the pandemic, COVID-19 are captured trough the variables 
Days since the first case until lockdown and BCG. Although they are already 
grouped in demographic characteristics, the main criterion for the insertion of 
the variables percentage older 65, percentage older 70 and diabetes_prevalence 
was the fact that they were mentioned in other studies. 
Regarding variable Days since the first case until lockdown, as mentioned in table 
6 it determines the number of days that each government took to decree a 
national lockdown after the first case in its country but it is important to take note 
that in the case of the countries where the lockdown was not decreed nationally, 
it was assumed the value of 154 days corresponding to the total of days in the 
sample of 22 weeks. The same for BCG, where in countries where there has never 
been a national policy for all, it was assumed a value of 100 years. 
Furthermore, regarding BCG, before taking this variable into consideration it 
was done a linear regression to test the effect of the vaccine in total deaths per 
COVID-19. 
 
The regression was the following: 
𝑑𝑒𝑎𝑡ℎ𝑠𝑐 =  𝛽0 +  𝛽1𝐵𝐶𝐺𝑐+ 𝑢𝑐 
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Where c represents the country. 
 
The results showed that BCG was a very significative variable explaining 
mortality for COVID-19, where an additional year of a country without policy of 
vaccination for all people implies an expected increase of 0,017 deaths per million 
in habitants. The R-squared of this regression is 10%, which indicates that 10% of 




4.3 Sampled Countries 
  
The countries used for the sample were selected by 2 criteria. 
In a first stage only countries that by the date of 10 May 2020 had more than 
3000 cases were collected to make it a significant sample.  
Considering this criterion, 66 countries were selected, and after this first 
selection, the data mentioned above for each of the 66 countries was searched. 
Since it was not possible to collect the test variable for the 66 countries, and it is 
a very important variable for the model, the countries where it wasn’t possible to 
collect the tests were eliminated, leaving 37 countries. 
On table 9 we can find on the left side the countries selected for the model, and 












Table 9- Countries Selection 









































4.4 Descriptive Statistics 
In table 10 we present the descriptive statistics for the used variables. 
Table 10- Descriptive statistic of variables 
Variable Min Max Mean Median Standard 
deviation 
cases 0 217714 6925 697,50 24405,61 
deaths 0 18302 500 22,5 1662,53 
tests 0 3029158 89030 18871 261776 
admin 0 57206 2237 143 6954,84 
uci_bed 0 18357 669 31 2071,82 
bed capacity 8663 938974 152641 71296 201403,2 
uci_capacity 303 70771 7284 2096 13485,17 
Days since the first 
case until lockdown 
9 154 52 52 63,18 
retail -91,43 17 -33,99 -31,72 31,63 
grocery -84,52 20 -13,96 -5,71 20,2 
parks -92,57 144,21 -8,92 0,00 40,83 
transit -87,43 17 -34,62 -39,57 30,37 
workplace -80,66 14,29 -27,99 -30,31 25,5 
residential -2,29 41,71 12,43 11,31 11,51 
Diabetes_prevalence 3,28 17,31 7,43 6,80 3,08 
Percentage older 65 4,8 23,02 14,39 16,76 5,63 








32365998   65681923 
population density 4,08 529,65 148,54 106,960 139,83 
Percentage RD LRI 
deaths 
4,46 17,84 9,62 9,15 3,3 




percentage of GDP 
3,9 16,94 8,45 8,86 2,69 
inv.helathcare per 
capita 
131 10586 3120 2780 2455,3 
physicians per 1000 
people 
0,8 5,4 2,95  3,1 1,17 
nurses per 1000 
people 
0,2 18,1 6,99 6,4 4,79 
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female smokers 0,2 34,2 16,65 18,80 9,33 
male smokers 9,9 50,1 28,84 28,90 9,98 
BCG 0 100 21,95 0,00 34,35 
 
 
For variables cases, deaths, tests, admin and uci_bed, their minimum value is 0 once 
the count started at 30.12.2020, after the first known case in China, where none of 
the selected countries was infected by COVID-19. In addition, as countries were 
affected at different times, while in some countries there were already several 
numbers for these variables, in others the number remained at 0. 
Regarding the variables above, the maximum value reached in a week was 
always by the United States of America where the maximum for cases was at 
week 15, for both deaths and hospitalizations was at week 16, tests was at week 
22 and hospitalizations in intensive care units was at week 17. 
Looking at the standard deviation for each of the variables, it is possible to notice 
that all of them are quite high which can be explained by the discrepancy of 
countries both in demographic and socio-economic terms.  
The variables related to mobility also have a large standard deviation evidencing 
the changes in mobility, compared to when the country was not affected by 
COVID-19 and when it becomes. 
Looking at the median, the variables where the difference between the mean and 
the median is starker are those that concern the capacity of beds in both hospitals 
and an ICU's, which indicates the presence of outliers like the USA that have an 
enormous capacity of beds. 
The variable Days since the first case until lockdown has a minimum of 9 days, 
which corresponds to the days that Peru took to enter national lockdown after 
the first case. The maximum value (154) was an assumed value for the study for 
countries that did not have lockdown and was calculated by (22*7) 
corresponding to the duration of the study, 22 weeks multiplying by 7 days. In 
this case the average is very biased by the countries that have not practiced 
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national lockdown  (United States of America, Turkey, Brazil, Egypt, Republic of 
Korea, Mexico, Canada, Philippines, Hungary, Sweden, Chile, Dominican 
Republic, Norway, Israel, Finland, Republic of Moldova). Therefore, looking 
only at the countries that practiced national lockdown, the average of days that 
they took to take the measure was 28 days. 
Finally, the variable BCG that has a minimum value of 0 for countries that 
maintain the national vaccination policy (Egypt, Republic of Moldova, Malaysia, 
Chile, Turkey,  Republic of Korea,  Philippines,  Romania,  Hungary, Poland,  
Portugal, Argentina, Ireland, Mexico, Dominican Republic, Brazil, Colombia, 
Peru and Panama) and a maximum value of 100 for countries that have never 
had a national vaccination policy (Belgium, Italy Netherlands, United States of 
America and Canada). Finally, countries that have had a national vaccination 
policy but have stopped having it for a few years where the minimum of 10 years 
is in Czechia and the maximum is 45 in Sweden. As the average considering the 
values 0 and 100 would be biased (21.95) was calculated the average of years 
considering only the countries that had national vaccination but no longer have, 
and the same is 23.85 years without vaccination of BCG. 
 
4.5 Choosing the right lag 
The first step before estimating the model was choosing the right lag to use for 
the estimation. The lag will be used on explanatory variables to better understand 
their effect on the final output, in this case, deaths.  
For example, it is not expected that the cases confirmed in one week, will affect 
the deaths of that current week, so, variable-specific lags were chosen by trial and 
error trying to maximize the goodness of fit for the selected model. 
 
4.6 Multicollinearity 
When trying to apply the variable population to the model, we faced a problem 
of multicollinearity since it had linear relations with variables like cases and tests. 
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To solve this problem, it was decided to change the dependent variable and all 
variables that were related with the population. 
So, instead of having a dependent variable deaths it as changed for deathspm 
(=(deaths/population)*1000000) )meaning the total deaths per million in habitants. 







4.7 Variables selection process 
To estimate the model, first all the variables were considered, and despite the 
R-Squared was 98%, most of the independent variables were meaningless. 
However, when analyzing carefully the variables it was possible to find a reason 
for the insignificance of some of them, which will be enumerated. 
4.7.1  Population Density 
The reason behind choosing variable population density in the model was the 
thought that when dealing with an infectious disease, countries with more 
aggregation of people would tend to have more risk of transmission and so, more 
cases and more deaths. What happened is that the variable didn’t have any 
influence in the model,  which can be explained by the fact that population 
density doesn’t consider large urban centers. For example, the population 
density of Portugal, doesn’t explain the difference between the aggregation of 
people in the centre of Lisbon and Aljustrel. Another example is Egypt that the 
population density is underestimated by the existence of deserts. 
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4.7.2 Percentage of RD LRI deaths 
This variable was considered to understand whether countries that already 
have high percentages of deaths from RD and LRI respond better or worse to this 
pandemic. 
This variable doesn’t have significance to the model and when analysing it 
with more attention it doesn’t allow to take any further conclusions. 
Looking for the relation between percentage of deaths in every country for 
respiratory diseases and low respiratory infections and total deaths, total cases, 
investment in healthcare, age of the population and healthcare resources in every 
country, this variable doesn’t show any evidence of relation with any of the 
variables.  
It might be associated with country’s specific characteristics, but it doesn’t 
allows any interpretation for the specific case of deaths per capita of the 
pandemic COVID-19. 
 
4.7.3 Bed_capacity, uci_capacity, Nurses and Physicians per 1000 people 
Healthcare resources doesn’t have significance in any model, and it can be 
justified in the same way it was for population density. For the case of Italy, for 
example, the capacity and resources available for all country doesn’t represent 
the lack of resources that were felt in Lombardia due to an enormous amount of 
COVID-19 hospitalizations. 
Anyway, to better corroborate the exclusion of these variables, there were created 
another two, to calculate hospitals and ICU’s occupation rate. 
The variables were as following:  
hospital_occupation=admin/bed.capacity,  
icu_ocupation= uci_bed/uci_capacity 
These variables not only came to be insignificant for the model but also showed 
that for the countries selected, the national mean occupation of hospitals 
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regarding COVID-19 patients was 1% and the national mean occupation of ICU’s 
regarding COVID-19 patients was 12% which can’t explain any impact in the 
mortality since the national resources were always more than enough. 
These averages for occupation might be overestimated since changes in 
countries’ capacity of hospitals and ICU’s to better respond to COVID-19 
pandemic weren’t considered.  
 
4.7.4 Female smokers and male smokers and country economic structure 
 
There wasn’t any result showing evidence of variable smokers in the output 
of COVID-19 per country. It might be the result of having the percentage of male 
smokers and female smokers per country but not the data regarding the percentage 
of men and women per country.  
For the economic structure of the country, nothing seems to have significance 
both in hospitalizations and in deaths per COVID-19. For example, the case of United 
States of America, that are by far the country with greatest GDP and investment in 
healthcare both per capita and per percentage of GDP and have a lot of 
hospitalizations and their ratio deaths/cases is way far from being the best. 
5. Results 
After excluding all the variables above, the next step was estimating the model. 
Deaths per million 
The model used for estimation is shown below where we can find variable 
testspm with a lag of 2 week,  casespm, adminpm and residential with a lag of one 
week and finally, uci_beppm with a lag of 0 weeks. The other variables are 




(3) 𝑑𝑒𝑎𝑡ℎ𝑠𝑝𝑚𝑐,𝑤 =  𝛽0 +𝛽1𝑡𝑒𝑠𝑡𝑠𝑐,𝑤−2+𝛽2𝑐𝑎𝑠𝑒𝑠𝑝𝑚𝑐,𝑤−1+𝛽3𝑎𝑑𝑚𝑖𝑛𝑝𝑚𝑐,𝑤−1 +
𝛽4𝑢𝑐𝑖_𝑏𝑒𝑑𝑝𝑚𝑐,𝑤 +𝛽5𝑋. . 𝑜𝑙𝑑𝑒𝑟. 70 𝑐 +𝛽6𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠_𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑐 +
 𝛽7𝑟𝑒𝑠𝑖𝑑𝑒𝑛𝑡𝑖𝑎𝑙𝑐,𝑤−1 +  𝑢𝑐,𝑤 
(4)  𝑢𝑐,𝑤=µ𝑐 + 𝑣𝑐,𝑤 




Where we can see that the total variance is 36,5 but the individual variance 
(country effect) is only 1,86. It shows that there is evidence of variability between 
countries, although it is in a very small percentage, 5,1% (last column). 




Applying Lagrange Multiplier Test, we could confirm that effectively, there is 






Applying Hausman test, we accepted the null hypothesis ( the hypothesis of 
non-correlated errors),  and the assumptions of the random effects model seem 
to be tenable for this data. 
Testspm (tests per million) and adminpm (hospitalizations per million) don’t 
seem to have significance in the model. However, as there is a very strong 
evidence of the significance of these variables to the mortality, it was decided to 
keep them and analyze their coefficients.  
Looking at the coefficients, in the cases of testspm we can observe that for one 
additional unit of tests per million, reduces mortality in 0,0001 per million two 
weeks after. Regarding casespm, one additional unit of cases per million, 
increases deaths per million in 0,014 one week later.  In the case of 
hospitalizations per million (adminpm), an additional unit of hospitalizations 
per million will increase the mortality per million in 0,0009 one week later. 
Hospitalizations in ICU, a very significant variable seems to strongly affect 
mortality, where in this case, an additional unit of hospitalizations in ICU per 
million (uci_bedpm) generates an increase of death per million in 0,095. 
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Regarding elderly population, when the percentage of people with age above 
70 increases 1%, the mortality per million increases in 0,194. The same for 
diabetes, when the percentage of diabetes prevalence increases 1%, deaths per 
million increase 0,241. 
Finally, the variable residential shows that a positive variation of 1% in the 
mobility on residential zones decreases deaths per million in 0,085 one week 
later. This model has a R-squared of 0,927 which means that 92,7% of COVID-19 
deaths per million can be explained by this model. 
Therefore, as expected the more people are tested, the more people are 
identified and in turn, isolated, reducing the risk of transmission. Thus, testing 
the population as much as possible has shown to be a solution to contain the 
transmission of COVID-19 and thus reduce the number of cases which will 
reduce hospitalizations both in hospital and ICU which are strongly correlated 
with deaths by COVID-19.  
In addition, age above 70 also revealed to be a contributing factor to mortality, 
something that would be expected to the extent that the symptoms caused by 
COVID-19 are mostly difficulty in breathing, which is a factor that is usually 
already a major obstacle for older people. 
The variable residential shows that effectively, confinement is a very 
important measure, since, when the greater the mobility in the residential area, 
the lower the mortality by COVID-19. Since there is a general belief that the  virus 
can be transmitted by asymptomatic people, and with the impossibility to test 
everyone, the more contact between people is avoided, the lower the risk of 







Intensive care units hospitalizations 
Looking again at the results of uci_bedpm, it can be interpreted that one out 
of ten people hospitalized in ICU is expected to die from COVID-19. So, we can 
interpret how hospitalized people in ICU affect mortality, but how is the 
hospitalization in ICU affected? 
To better answer this question, it was estimated another model where the 
dependent variable was hospitalizations per million in ICU (uci_bedpm). 
The model was estimated using the same variables as the model before but all 
the other variables were again tested. 
Intensive care units hospitalizations per million 
(5) 𝑢𝑐𝑖_𝑏𝑒𝑑𝑝𝑚𝑐,𝑤 =  𝛽0 +𝛽1𝑡𝑒𝑠𝑡𝑠𝑐,𝑤−2+𝛽2𝑐𝑎𝑠𝑒𝑠𝑝𝑚𝑐,𝑤−1+𝛽3𝐵𝐶𝐺 𝑐  +
𝛽4𝑋. . 𝑜𝑙𝑑𝑒𝑟. 70 𝑐 ++ 𝛽5𝑟𝑒𝑠𝑖𝑑𝑒𝑛𝑡𝑖𝑎𝑙𝑐,𝑤−1 +  𝑢𝑐 
(6) 𝑢𝑐,𝑤=µ𝑐 + 𝑣𝑐,𝑤 
 
And the results were: 
                                 
 
Where we can see that the total variance is 310,38 and the individual variance is 
86,85. It shows that there is evidence of variability between countries, where 28% 
of the error’s variance are affected by the country effect.  Interesting that variance 
between countries is much bigger and that the country has an effect here. This 
reveals that the country is not a very important factor in explaining deaths, but it 
is very important in explaining ICU hospitalizations, which may reveal different 






Applying once again the Lagrange Multiplier Test we could prove the country 




With Hausman Test we could again accept the null hypothesis and use the 
estimation of random effects panel models. 
All the variables excluded from the previous model were again excluded in this 
one except the variable BCG. 
Regarding tests per million, an additional unit of tests per million, reduces 
hospitalizations per million in intensive care units in 0,0091 two weeks later.  
Variable cases per million, as in the previous model affects positively 
hospitalizations in ICU, where an additional unit of cases per million increases 
0,776 hospitalizations per million in ICU one week later. 
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Despite the previous model, BCG vaccination has significance to hospitalizations 
in ICU where an additional year of a country without policy of vaccination for 
all people increases 0,073 hospitalizations per million in ICU.  
As expected, age affects hospitalizations in ICU, where an additional 1% of 
people above 70 years in a country, might increase 6,76 hospitalizations per 
million in ICU. 
The variable residential shows that a positive variation of 1% in the mobility on 
residential zones decreases hospitalizations per million in ICU in 1,87 one week 
later. This model has a R-squared of 0,657 which means that 65,7% of COVID-19 
hospitalizations per million in ICU can be explained by this model. 
 
Finally, it was estimated the same model for hospitalizations per million to 
understand if there is any variable that differentiate hospitalizations and 
hospitalizations in ICU.  
Hospitalizations per million 
 
(7) 𝑎𝑑𝑚𝑖𝑛𝑝𝑚𝑐,𝑤 =  𝛽0 +𝛽1𝑡𝑒𝑠𝑡𝑠𝑐,𝑤−2+𝛽2𝑐𝑎𝑠𝑒𝑠𝑝𝑚𝑐,𝑤−1+𝛽3𝐵𝐶𝐺 𝑐  +
𝛽4𝑋. . 𝑜𝑙𝑑𝑒𝑟. 70 𝑐 +  𝛽5𝑟𝑒𝑠𝑖𝑑𝑒𝑛𝑡𝑖𝑎𝑙𝑐,𝑤−1 +  𝑢𝑐 
(8) 𝑢𝑐,𝑤=µ𝑐 + 𝑣𝑐,𝑤 
 
And the results were as following: 
 
Where we can see that the total variance is 3551,89 and the individual variance is 
773,68. It shows that there is evidence of variability between countries, where 






Finally,  in this model we could again observe the existence of variability between 
countries and prove the country effect. 
 
 
The estimation of random effects panel models was again used since we could 
accept the null hypothesis of the Hausman Test and so, accept the assumptions 
of random effects panel models. 
The results were very similar to the model estimated for hospitalizations in ICU 
where all other variables remain insignificant and BCG continues to affect 
positively hospitalizations per million. This model has a R-squared of 0,553 
which means that 55,3% of COVID-19 hospitalizations per million can be 






This variable seems to affect mortality but when introduced on models to explain 
the two kind of hospitalizations it doesn’t have any significance. 
In fact, it makes some sense, because diabetics don’t have higher probability of 
getting infected with COVID-19, but, once they get, their outcome is more likely 
to be the worst of the scenarios.  
In fact, in a recent publication in MedScape, Tucker (2020) conclude that 10% of 




The variable BCG vaccination didn’t have any significance when trying to 
explain deaths per million of COVID-19, nevertheless, it helped explaining both 
normal hospitalizations of patients COVID-19 and hospitalizations in ICU of 
patients with COVID-19. 
It was decided to analyze some evidence between BCG vaccination and the ratios 
deaths/cases and uci_bed/cases because of the evidence mentioned earlier in 
other studies that the BCG vaccination seems to have protective effects against 
respiratory infections, mitigating the symptoms and reducing mortality. And by 
looking at table 12 we can see that the worst ratios are mainly in countries that 











UCI_beds  Deaths/Cases UCI/Cases BCG 
Chile 94858 997 1325 0,01 0,01 0 
Malaysia 7762 115 197 0,01 0,03 0 
Israel 17012 284 429 0,02 0,03 38 
Republic of Korea 11471 270 378 0,02 0,03 0 
Panama 13018 330 490 0,03 0,04 0 
Turkey 163103 4515 6930 0,03 0,04 0 
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Norway 8411 236 334 0,03 0,04 11 
Peru 155671 4371 10604 0,03 0,07 0 
Dominican Republic 16908 498 790 0,03 0,05 0 
Colombia 28236 890 1223 0,03 0,04 0 
Argentina 16111 518 768 0,03 0,05 0 
Czechia 9230 319 452 0,03 0,05 10 
Republic of Moldova 8098 291 373 0,04 0,05 0 
Egypt 23449 913 1560 0,04 0,07 0 
Austria 16638 668 873 0,04 0,05 30 
Portugal 32203 1396 1797 0,04 0,06 0 
Poland 23571 1061 1464 0,05 0,06 0 
Finland 6826 314 424 0,05 0,06 14 
Germany 181482 8500 11238 0,05 0,06 22 
Denmark 11633 581 793 0,05 0,07 34 
United Kingdom 733669 38376 52592 0,05 0,07 15 
Switzerland 30762 1655 2594 0,05 0,08 33 
Philippines 17224 950 1637 0,06 0,10 0 
Brazil 498440 28834 42628 0,06 0,09 0 
United States of America 1770384 103781 126105 0,06 0,07 100 
Romania 19133 1253 1675 0,07 0,09 0 
Ireland 24929 1650 2337 0,07 0,09 0 
Canada 90179 7073 9288 0,08 0,10 100 
Ecuador 38571 3318 8889 0,09 0,23 6 
Mexico 87512 9779 7519 0,11 0,09 0 
Spain 239068 27127 37964 0,11 0,16 39 
Sweden 37113 4395 5820 0,12 0,16 45 
Netherlands 46257 5951 8173 0,13 0,18 100 
Hungary 3867 524 687 0,14 0,18 0 
Italy 232664 33340 43389 0,14 0,19 100 
Belgium 58186 9453 12620 0,16 0,22 100 




It isn’t an obvious relation, but it seems to be some evidence regarding the 
vaccination of BCG and the output of deaths/cases and UCI/cases.  
So, as vaccination helps mitigating some symptoms it explains why countries 
with no vaccination tend to have more hospitalizations both normal and in ICU 




One reason to explain this results might be the quality of the data since 
countries have different criteria when considering deaths per COVID-19, which 
might have influenced the result of the estimation of the model deaths per 
COVID-19 and so, affected the coefficients and significance of some variables.  
 
Variables of mobility  
As we can see in the final model, only the variable residential was significative 
in the model but it is important to note that there is a very strong correlation between 
this variable and the other variables of mobility. 
 transit workplace retail grocery parks 
residential -0,96 -0,97 -0.96 -0,92 -0,65 
 
There are very strong negative relations between residential and transit, 
workplace, retail and grocery which mean that they strongly grow in opposite 
directions. As more people stayed at their residential area, the mobility in public  
transports, workplaces, retail and leisure and supermarkets and pharmacies 
had strongly decreased.  
The relation between residential and parks is still negative, which means that 
they still grow in opposite directions, but it isn’t as stronger as the relations before 
which makes a lot of sense when looking to what is happen around the world. With 
the shutdown of gyms, malls cafes and other areas of leisure, people tend to start 
using more and more parks to do exercise, pet their dogs, go for a walk, simply not 









In conclusion, there is effectively no evidence that the economic structure of the 
country affects its mortality. Like the case of the United States of America which 
has one of the strongest economic structures in the world and in terms of the 
death-to-case ratio per COVID-19, are among the worst outcomes. In addition, 
Shet et al. (2020) had even found counterintuitive results between the economic 
structure and the output of the country, in which countries with higher GDP had 
worse results in terms of mortality. 
Regarding healthcare resources, no evidence was found. However, this study 
presents some limitations so that it is not possible to draw conclusions about the 
importance of healthcare resources for the country's results in terms of mortality. 
This is because in our study we talked about national capacity, but mortality in 
countries was often affected by strong contagion in regional terms. For example, 
in Italy, in the south, the pandemic was hardly felt, healthcare resources were 
practically unused, but in the Lombardy area, resources were insufficient, we 
saw a lot of news that showed the stocking and chaos that were the hospitals and 
the ICU's in that area. Nevertheless, in this study, situations such as this were not 
taken into account, and, therefore, it is possible to say that the national capacity 
for resources does not affect mortality, but it is not possible to say that the 
resources in particular do not affect it. 
Regarding comorbidities, it was possible to observe that countries with a 
higher percentage of diabetics have worse results in terms of mortality, and that 
countries that do not have a national vaccination policy for BCG were also more 
affected. 
Regarding the response time of each country, there is no evidence that the time 
it took them, if they did, to enter lockdown, have contributed to mortality. This 
also has a lot to do with the attitude of the population, and therefore the variables 
of mobility ended up explaining this situation much better. For example, in 
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Portugal, even before the lockdown was enacted, people voluntarily started 
staying at home and many customer service establishments began to close on 
their own initiative. Moreover, in some countries the national lockdown was not 
enacted because the situation did not require it, since the contagion was very 
regional, and it was enough to isolate the region in question. 
The measure of "stay at home" effectively has an impact on mortality. Given a 
pandemic in which the main objective is to have the minimum number of 
contagion to be more easily controllable in terms of resources, the more people 
stay at home, the less contact there is, so fewer cases, so fewer hospitalizations, 
so less burden in hospitals and health professionals, so fewer deaths. 
 
It is important to note that this study has some limitations in terms of data, 
more specifically in terms of covid-19 mortality. This is because countries have 
different criteria for considering deaths from COVID-19. 
For example, France only includes data on those who die in hospitals, and Spain 
does not record untested deaths in nursing homes for the elderly. 
 
Finally, as a proposal for future investigations, it would be interesting to study 
the impact of variables of hospital resources at the regional level to understand 
whether there is effectively an impact in terms of bed resources and health 
professionals. 
In addition, to find a criterion for standardizing deaths recorded by COVID-
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